Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain

BMC Cancer

Emilio Álvarez-Fernández¹  Ernesto Moro-Rodríguez²  Benjamín García-Espinosa³ 

[1]Department of Anatomical Pathology and Laboratories, Hospital General Universitario “Gregorio Marañón”, Madrid, Spain

[2]Universidad Rey Juan Carlos, Av de Atenas s/n., E28922 Alcorcón, Madrid, Spain

[3]Department of Histology and Anatomical Pathology, Rey Juan Carlos University School of Medicine, Madrid, Spain

关键词: Spain;    Cervix;    Squamous intraepithelial lesions;    Genotyping;    Polymerase chain reaction;    Human papillomavirus;   

Others  :  1080078
DOI  :  10.1186/1471-2407-12-533

 received in 2012-04-28, accepted in 2012-10-30,  发布年份 2012

【 摘 要 】

Background

Human Papillomavirus (HPV) genotype distribution and co-infection occurrence was studied in cervical specimens from the city of Madrid (Spain), as a contribution to the knowledge of Human Papillomavirus genotype distribution and prevalence of carcinogenic HPV types in cervical lesions in Spain.

Methods

A total of 533 abnormal specimens, from the Hospital General Universitario “Gregorio Marañón” of Madrid, were studied. These included 19 benign lesions, 349 cervical intraepithelial neoplasias 1 (CIN1), 158 CIN2-3 and 7 invasive cervical carcinomas (ICC). HPV genotyping was performed using PCR and tube array hybridization.

Results

We detected 20 different HPV types: 13 carcinogenic high-risk HPV types (HR-HPVs), 2 probably carcinogenic high-risk HPV types (PHR-HPVs) and 5 carcinogenic low-risk HPV types (LR-HPVs). The most frequent HPV genotypes found in all specimens were HPV16 (26.0%), 31 (10.7%) and 58 (8.0%). HPV 18 was only detected in 5.0%. Co-infections were found in 30.7% of CIN 1 and 18.4% cases of CIN2-3. The highest percentage of HR HPVs was found in those specimens with a CIN2-3 lesion (93.7%).

Conclusion

As our study shows the current tetravalent vaccine could be effective in our geographical area for preventing all the invasive cervical carcinomas. In addition, upon the estimates of the important presence of other HR-HPV types – such as 31, 58, 33 and 52 – in different preneoplasic lesions the effectiveness of HPV vaccination in our geographical area, and others with similar genotype distribution, should be limited.

【 授权许可】

   
2012 García-Espinosa et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Schiffman M, Clifford G, Buonaguro FM: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8. BioMed Central Full Text
• [2]Pfister H: Human papillomaviruses and genital cancer. Avd Cancer Res 1987, 48:113-147.
• [3]De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H: Classification of papillomaviruses. Virology 2004, 324:17-27.
• [4]Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
• [5]Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis or atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007, 195:1582-1589.
• [6]Schiller JT, Lowy DR: Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol 1996, 7(6):373-382.
• [7]Zhow J, Sun XY, Stenzel DJ, Frazer IH: Expression of vaccine recombinant HPV 16 L1 nd L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185(1):251-257.
• [8]Kirnbauer R, Chandrachud LM, O’Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996, 219:37-44.
• [9]Conesa-Zamora P, Ortiz-Reina S, Moya-Biosca J, Doménech-Peris A, Orantes Casado FJ, Pérez-Gufillermo M, Egea-Cortines M: Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain. BMC Infect Dis 2009, 9:124. BioMed Central Full Text
• [10]Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, The HPV PATRICIA Study Group: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(1):89-99.
• [11]Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1157-1164.
• [12]De Sanjose S, Almiral R, Lloveras B, Font R, Diaz M, Muñoz N, Català I, Meijer CJ, Snijders PJ, Herrero R, Bosch FX: Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003, 30:788-793.
• [13]De Oña M, Alvarez-Argüelles ME, Torrents M, Villa L, Rodriguez-Feijoo A, Palacio A, Boga JA, Tamargo A, Melón S: Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol 2010, 82:597-604.
• [14]González C, Ortiz M, Canals J, Muñoz L, Jarrín I, de la Hera MG, García-Saiz A, del Amo J: Higher prevalence of human papillomavirus infection in migrant women from Latin America in Spain. Sex Transm Infect 2006, 82:260-262.
• [15]García-Espinosa B, Nieto-Bona MP, Rueda S, Silva-Sánchez LF, Piernas-Morales MC, Carro-Campos P, Cortés-Lambea L, Moro-Rodríguez E: Genotype distribution of cervical human papillomavirus DNA in women with cervical lesions in Bioko, Ecuatorial Guinea. Diagn Pathol 2009, 4:31. BioMed Central Full Text
• [16]Bernal M, Burillo I, Mayordomo JI, Moros M, Benito R, Gil J: Human papillomavirus (HPV) infection and intraepithelial neoplasia and invasive cancer of the uterine cervix: a case–control study in Zaragoza, Spain. Infect Agent Cancer 2008, 3:8. BioMed Central Full Text
• [17]Cobo F, Concha A, Ortiz M: Human papillomavirus (HPV) type distribution in females with abnormal cervical cytology. A correlation with histological study. Open Virol J 2009, 3:60-66.
• [18]De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
• [19]García-García JA, Pérez-Vallés A, Martorell M, Gómez B, Gómez-Cabrero D, Soler F, Calabuig C: Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. Acta Cytol 2010, 54:159-164.
• [20]Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(S3):26-34.
• [21]Lacruz Pelea C, Di Martino Ortiz B, Álvarez Fernández ÁFE: Incidencia de los diferentes tipos de papiloma virus humano (HPV) en las lesiones escamosas del cérvix uterino. Rev Es Patol 2003, 36(1):79-84.
• [22]Doménech-Peris A, Conesa-Zamora P, Sahuquillo-Frias L, Ortiz-Reina S, Moya Biosca J, Acosta-Ortega J, Pérez Guillermo M, Egea-Cortines M: Human papillomavirus genotyping in histological sections of precursor lesions of cervical carcinoma: its role as a possible adjunct for the evaluation of the oncogenic potential of specific human papillomavirus genotypes – a study in a coastal region of Southeastern Spain. Gynecol Obstet Invest 2010, 70:113-119.
• [23]Lacruz Pelea C, Muñoz Fernández de Legaria M: Vacunas VPH: lesiones de cérvix y tipos virales asociados en la Comunidad de Madrid. Rev Es Patol 2009, 42:121-125.